Jump to content

Search the Community

Showing results for tags 'side effects'.

More search options

  • Search By Tags

    Type tags separated by commas.
  • Search By Author

Content Type


    • Announcements, meetings and other resources
    • Primary hormone therapy
    • Secondary hormone therapy
    • Castrate Resistant Prostate Cancer
    • Metastatic
    • Very high risk
    • New agents
    • Every little bit helps
    • Radiation, diagnostic imaging, bones and other prostate cancer topics
    • Articles on other sites
    • My story
    • Any suggestions?
    • The lounge

Find results in...

Find results that contain...

Date Created

  • Start


Last Updated

  • Start


Filter by number of...

Found 29 results

  1. I was diagnosed with an aggressive prostate cancer (Gleeson 10) in June 2017. Following the diagnosis I was immediately put on ADT using Zolodex and have been on it continuously since. I have also undergone 8 weeks of radiation therapy. To date treatment has been successful and I have had a PSA level of 0.02 for about the last 18 months. My problem is that I have uncontrollable mood swings in which I become quite angry and short tempered. I also have thoughts that have no basis in reality during these swings which is putting considerable pressure on my family. My trouble is that I can feel the mood change coming on but do not seem to be able to control it. I have considered seeking professional psychological/psychiatric help but before I do was wondering if anyone on this forum has experienced this whilst on ADT and if so how do you overcome or control them. Any advice would be welcome.
  2. This video today is about weight training for men on hormone therapy for prostate cancer. Hormone therapy is also called 'Androgen Deprivation Therapy' (ADT) because it robs a man of androgens. The main androgen is testosterone. Androgens fuel prostate cancer. And a reminder that we have a few videos of our own on the JimJimJimJim channel: https://www.youtube.com/jimjimjimjim/videos The Prostate Cancer Research Institute (PCRI) is an important source of information for about prostate cancer for patients, families, and the medical community. As part of their mission to empower men and their caregivers they make YouTube videos.
  3. alanbarlee

    Hot flushes from ADT

    Margaret asked about hot flushes at our September 2019 call-in conference. Here's some up-to-date information from one our leading urologists. Hot flushes (extracts from ACCP Consensus Conference 2019 - UroToday) The important topic of hot flushes caused by androgen deprivation therapy (ADT) was discussed by Dr. Frydenberg (Melbourne urologist). Hot flushes are defined as a subjective feeling of warmth in the upper torso, followed by excessive perspiration. Approximately 80-90% of men on ADT endure hot flushes, with 27% reporting them as the most troublesome side effect. Hot flushes have been associated with patient embarrassment, helplessness, and distress during treatment. They can last for the entire duration of treatment and significantly affect quality of life and sleep. The reduction of plasma sex hormones levels from previous normal levels alters the function of brain neurotransmitters such as noradrenaline, serotonin, GABA, dopamine, and beta-endorphins. The thermoregulatory centre in the hypothalamus is anatomically close to the LHRH secreting neurons, and by proximity, the thermoregulatory centre can be reset. There is a positive correlation between hot flushes and LH surges. Hot flushes have been reported to worsen with longer ADT treatment durations and are also worse in younger men with lower BMI.3 Some complementary treatments that can be used include: Exercise – especially high-intensity aerobics and resistance training Cognitive-behavioural therapy Diet – no benefit has been shown in randomized controlled trials for phytoestrogens Acupuncture – reports of 70-80% reduction in flushes with either dry needling or electro stimulated needling. Moreover, patients maintained less than 50% reduction in their hot flushes 9 months after cessation of treatment in 46% of patients. Hot flushes are a common and troublesome side effect of ADT. It is imperative that patients avoid known triggers of hot flushes and promote conservative therapies. An intermittent androgen blockade is a good option where appropriate and safe. It is reasonable to consider progesterone and SSRI/SNRI (anti-depressants) as first-line medical therapy. Lastly, complementary therapies are always recommended (acupuncture and exercise).
  4. Kezza2

    Now for Docetaxel

    Well gentlemen, The time has come. I was on abiraterone + apelutimide trial for two years until that failed, and swapped to enzalutimide (Xtandi) but that only lasted three months, and now my PSA has more than doubled from 17 to 38 in 6 weeks, so it seems that docetaxel is next on the list. Having not had docetaxel previously I am not a candidate for the Lu177 trial unfortunately, so I am scheduled to start docetaxel in two weeks. I would appreciate any words of wisdom from the wise who have already been through this on side effects and how to avoid or minimise them, and what I may expect.
  5. AnCan 5th Monday Plenary .... Cancer, Sleep & Dreams Tuesday,Jan 30 - Brisbane: Tuesday 30 January 11AM Sydney: Tuesday 30 January Noon Adelaide: Tuesday 30 January 11:30AM Perth: Tuesday 30 January 9AM Joining instructions below pdf attached Hello Friends - One subject we all experience, often in a highly compromised fashion after diagnosis, is SLEEP! It rarely gets addressed ... we just take it for granted even though we spend a third of our lives trying to practice it. How many of you have raised sleep issues with your medical team? How many of you realize many of your side effects are sleep related? AnCan is hosting a rarely addressed topic in our 5th Monday plenary .... 'Cancer & Sleep'. We welcome Dr. Rubin Naiman, a recognized sleep expert who is a colleague of Andrew Weil at the Arizona Integrative Medicine Center. While the presentation addresses all cancers, PCa will get special attention. A pdf is attached and the URL is https://www.ancan.org/cancer-sleep-dreams - this subject impacts most survivors but is all too often swept under the carpet. Please join us and spread the word to others that may be impacted. Questions can be submitted ahead of time to info@ancan.org; or, submitted via the Chat Window if you join online. For phone participants, slides will be available at https://www.ancan.org/cancer-sleep-dreams at least 24 hours prior. If the GoToMeeting Virtual Room is full, please join by phone. Onward & upwards, rick PS Recording should be available within 24 hrs after at https://www.ancan.org/cancer-sleep-dreams JOINING INSTRUCTIONS ONLINE Answer Cancer Meeting Room: Click here or paste https://www.gotomeet.me/AnswerCancer into your browser You will be using your microphone and speakers (VoIP) - to minimize background noise, please mute your mic when not speaking. First GoToMeeting? Do a quick system check: https://link.gotomeeting.com/system-check If the GoToMeeting Virtual Room is full, please join by phone & download slide presentation PHONE United States +1 (646) 749-3129 Canada +1 (647) 497-9353 Australia +61 2 8355 1020 United Kingdom +44 330 221 0088 Access Code: 222-583-973 -- Rick Davis, Founder +1 415 505 0924 rd@ancan.org Next AnCan Women's Breast Cancer Group Feb 1, 2018 - info on website ... spread the word. Next AnCan Men's Breast Cancer Group Feb 22, 2018 - info on website ... spread the word. Answer Cancer Foundation https://www.ancan.org Facebook A Minnesota 501c3 Corp, EIN 81-1588152 6905 Rosemary Road, Eden Prairie MN 55346 If this communication was helpful, please consider a donation! Cancer & Sleep plenary promo final sm.pdf
  6. Prostate Cancer Hormone Therapy Study Have you received hormone therapy treatment for prostate cancer? If so, you may be eligible to join an American Cancer Society funded study to test a program designed to help people with changes to memory, thinking and concentration following hormone therapy for treatment of prostate cancer. This study is done completely over the phone and internet and involves a brief screening to determine eligibility, 3 assessments/interviews, and 8 weeks of home-based computer use. For more information, please contact Lisa Wu at +1 (212) 824-7805 or lisa.wu@mssm.edu This study is approved by the Mount Sinai Institutional Review Board (GCO# 10-1352 approved through 6 April 2015) Dr Lisa Wu is an Instructor in the Department of Oncological Sciences in the Icahn School of Medicine at Mount Sina, New York, one of the leading medical schools in the United States. For a number of years Lisa's work has focused on research into quality of life issues around cancer patients experiencing cognitive difficulties after treatment. Lisa already has a number of men from Australia participating in this study. She is wanting to recruit more Australian men who have had hormone therapy treatment. Given the time difference, sending an email to Lisa is probably the easiest way to make initial contact.
  7. "TAPS stands for “taxane acute pain syndrome”. It is a recognized side effect of treatment with taxanes like docetaxel. It is usually characterized by muscular pain (myalgia) and joint pain (arthralgia) that starts about 24 to 48 hours after taxane treatment and then lasts for up to about 7 days. However, relatively little is known about its incidence and predisposing factors in men with prostate cancer who are being treated with taxane-based chemotherapy..................... The “New” Prostate Cancer InfoLink would suggest that the risk for TAPS is something that needs to be explained to patients prior to their chemotherapy along with guidance about (a) how to address this type of side effect should it occur and (b) the importance of reporting this side effect to their doctors." Click here to read the article from The “New” Prostate Cancer InfoLink.
  8. " In what seems to be a first, study researchers are saying that they might have uncovered a link between ADT and Alzheimer’s. Their study is small and preliminary and it does not prove a cause-and-effect relationship, but merely shows an association between ADT and Alzheimer’s disease." Click here to read more.
  9. Joel Nowak of Malecare reports on an abstract presented at the 2016 American Society of Clinical Oncology (ASCO) Scientific Meeting about how abiraterone (brand name Zytiga) and enzalutamide (brand name Xtandi) may cause cognitive impairment and mood changes. Interestingly the research showed that these side effects were more prevalent with enzalutamide than with abiraterone. Click on this link to read the Malecare report..
  10. Having incurable cancer has caused Larry Axmaker to adjust his definition of "quality of life". Click here to read about how Larry defines "quality of life"
  11. Paul Edwards

    Firmagon injection - minimising side effects

    One of the drugs used in androgen deprivation therapy is Firmagon (degarelix). Firmagon requires a monthly injection. There can be severe pain at the site of the injection (caused by bruising and rashes which can last for 3-4 days each month). This post has been updated with additional suggestions about how to miminise the pain from a Firmagon injection.
  12. We are all familiar with the concept of intermittent ADT as opposed to continuous ADT. Now researchers are investigating the concept of intermittent chemotherapy as opposed to continuous chemotherapy. If certain criteria are met, there will a break in the chemotherapy treatment and the patient will have a “drug holiday”. In theory intermittent chemotherapy may serve 2 purposes. First, with less constant exposure to the drug, this may potentially delay the development of taxane-refractory disease. Second, breaks in therapy or “drug holidays” may improve the quality of life for patients, allowing them to recover from the cumulative toxicity of chemotherapy during these “drug holidays.” Resolution of drug side effects may also allow taxane therapy to be prolonged, which could also improve outcomes. It is interesting to see that one of the abstracts for the 2016 ASCO (American Society of Clinical Oncologists) meeting in Chicago next week is about “PRINCE: A phase III study comparing intermittent docetaxel therapy versus continuous docetaxel therapy in patients with castration-resistant prostate cancer”. PRINCE which was a study conducted by German researchers found that: “The intermittent docetaxel chemotherapy was non-inferior to a continuous therapy in one-year survival. It was well tolerated and may present a treatment option for patients with CRPC”. Reference: http://abstract.asco.org/176/AbstView_176_170886.html
  13. Peripheral neuropathy is a common side effect of chemotherapy treatment for prostate cancer. Patients who suffer from this condition have damage to their peripheral nerves and experience weakness, numbness and pain usually in their hands or feet and occasionally in other areas of the body. Researchers at the Moffatt Cancer Center at Tampa, Florida have found that genetic alterations in the VAC14 gene are associated with an increased risk of docetaxel-induced peripheral neuropathy in prostate cancer patients. This discovery may help scientists to understand what causes docetaxel-induced neuropathy and to develop drugs that can reduce peripheral neuropathy.
  14. Depression resulting from Androgen Deprivation Therapy is a completely under-recognized phenomenon, according to a recent article. Click on this link to read the article. Beyond Blue 1300 22 4636 and Lifeline 13 11 14 provide support for depression.
  15. Paul Edwards

    Help! - Hot flushes

    One of our members has just started ADT and complains "These hot flushes are still coming every 30 minutes 24/7. It's nearly 4am and just been woken up again covered in sweat!" What worked for you when you were battling with hot flushes?
  16. ADT carries with it a heightened risk of depression as well as cognitive effects. The cognitive impact, though, is neither well defined nor consistent. The data collectively suggest that the negative impact of ADT on patients directly (and on their intimate partners indirectly) are greater for younger than older men. Across the array of adverse effects, physical exercise appears to have the greatest potential to address the psychological effects of ADT, both in men who are receiving ADT and in their partners. Donovan KA, Walker LM, Wassersug RJ, Thompson LM, Robinson JW. 2015. Psychological effects of androgen-deprivation therapy on men with prostate cancer and their partners. Cancer [epub ahead of print] 15 September 2015. www.ncbi.nlm.nih.gov/pubmed/26372364 From Richard Wassersug's Life on ADT Blog
  17. Chemotherapy can cause peripheral neuropathy (damage to your peripheral nerves). Peripheral neuropathy often causes weakness, numbness and pain, usually in your hands and feet. A study of female cancer survivors found that almost half experience chemotherapy-induced peripheral neuropathy symptoms years after completing their cancer treatment. These symptoms were associated with impacts including reduced mobility and significantly increased risk of falls. The results were presented at the American Society of Clinical Oncology (ASCO) Cancer Survivorship Symposium held in San Francisco. The lead researcher said that it is likely that the findings may be applicable to male cancer survivors as well. Click on this link to read the article.
  18. Paul Edwards

    ADT negatively affects mood

    Researchers asked prostate cancer patients to fill in an online questionnaire on their mood in relation to the prostate cancer treatments they had received. Their results showed that, compared to patients not on ADT, ADT does indeed negatively affect the mood of men, most notably increasing their sense of fatigue and decreasing their sense of vigor. The authors also asked partners of patients to rate the patients’ moods. The partners reported similar declines in the patient’s mood that the patients reported, but to a greater degree than the patients themselves. Often our partners know us better than we know ourselves. Van Dam D, Wassersug RJ, Hamilton LD. Androgen deprivation therapy’s impact on the mood of prostate cancer patients as perceived by patients and the partners of patients. Psycho-Oncology 2015; [epub ahead of print] 31 August 2015. www.ncbi.nlm.nih.gov/pubmed/26332203
  19. A retrospective study of nearly 17,000 patients has suggested that androgen-deprivation therapy (ADT) is associated with an increased risk for the future development of Alzheimer's disease in men with prostate cancer,. Click here to read a report in the New Prostate Cancer Infolink about the study. Researchers can’t prove a direct cause-and-effect link between ADT and Alzheimer’s in an observational study like this. Some other unknown variable might be influencing the results........ Given that it’s a first-time association in a retrospective analysis, this study helps inform future research but it’s not appropriate at this point to make treatment decisions off of it......... If your doctor has put you on this medication for your prostate cancer treatment, you should continue it. Consult with your physician, but don’t stop taking your medication based on a study like this....
  20. According to this WebMD paper, for patients prescribed the anticoagulant (blood thinner) warfarin there is a long list of medications that both patient and treating doctor must be aware as causing severe to serious to moderate side effects: http://tinyurl.com/qcafmkw Interesting, among them, are several that prostate cancer patients are prescribed including NSAIDs (identified here http://tinyurl.com/nhtjyvh), enzalutamide, corticosteroids (thus prednisone if prescribed abiraterone), acetaminophen, and several others. If you're a patient prescribed warfarin and also prescribed any of the medications listed, best to discuss with your treating doctor in order to watch diagnostics closely if the combination of these medicines with warfarin is necessary.
  21. I got asked by someone about handling the side effects from chemo. Here are some suggestions. Click on this link for some suggestions from the Cancer Council. Click on this link for a research study which looked at the evidence for what works and what doesn’t. Do any members have other suggestions of what worked for them?
  22. Paul Edwards

    Xofigo Update

    The US Federal Drugs Administration approved the use of Radium 223 (Brand name Xofigo also called Alpharadin) two years ago. The well-known US prostate oncologist Dr Mark Scholz gives an update on the experience of his clinic in using the drug. Click on this link to read his article. Xofigo is not yet available in Australia on the PBS
  23. A good video by the Prostate Cancer Canada Network Calgary. Psychologists from the Tom Baker Cancer Centre in Calgary Canada, Lauren M. Walker and John W. Robinson, share a talk the context of when Androgen Deprivation Therapy, or ADT, is used for treatment. They also talk about the studies and work they've done on the treatment, the side effects and ways to deal with them.
  24. An interesting article about a presentation on hormone therapy made by Australian researchers to this year's American Society of Clinical Oncology (ASCO) Annual Meeting. Click on this link to read it.
  25. The Prostate Cancer Foundation of Australia has posted a video on YouTube of the following talk on Radiation Therapy for Prostate Cancer given by radiation oncologist A/Prof Michael Izard at Sydney Adventist Hospital on 22 June 2015 .
  • Create New...